Michael Darsley
Corporate Officer/Principal bei Minervax ApS
Profil
Michael Darsley is currently the Head of Clinical Development at Minervax ApS.
Previously, he held positions as Director of Vaccine Development at Cambridge Biostability Ltd., Vice President of Bacterial Research at Acambis Plc, Principal at IGEN International, Inc., Chief Development Officer at ACE BioSciences ApS and TD Vaccines A.
He also worked as a Principal at the National Cancer Institute.
Darsley received his undergraduate and doctorate degrees from the University of Oxford.
Aktive Positionen von Michael Darsley
Unternehmen | Position | Beginn |
---|---|---|
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Michael Darsley
Unternehmen | Position | Ende |
---|---|---|
IGEN International, Inc.
IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
TD Vaccines A/S
TD Vaccines A/S Pharmaceuticals: MajorHealth Technology TD Vaccines A/S S is a holding company that focuses on the development of vaccines to protect against travellers' diarrhoea (TD). It is a biotechnology company that discovers and develops novel vaccines to fight serious bacterial infections. Its lead programme is ACE527, an oral ETEC vaccine to protect against ETEC (Enterotoxigenic E Coli). Its oral combination vaccine, ACE920, designs to protect against ETEC and Campylobacter infections. The company was founded in November 2009 and is headquartered in Skorping, Denmark. | Corporate Officer/Principal | - |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
Cambridge Biostability Ltd.
Cambridge Biostability Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Biostability Ltd. manufactures vaccines and drugs. The firm's two platforms VitRIS and HydRIS offers pharmaceuticals, vaccines, and other biological products in thermo-stable, instantly-injectable formats. The company was founded by Dr Bruce Roser in 2003 and is headquartered in UK. | Corporate Officer/Principal | - |
Ausbildung von Michael Darsley
University of Oxford | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 7 |
---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
Cambridge Biostability Ltd.
Cambridge Biostability Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Biostability Ltd. manufactures vaccines and drugs. The firm's two platforms VitRIS and HydRIS offers pharmaceuticals, vaccines, and other biological products in thermo-stable, instantly-injectable formats. The company was founded by Dr Bruce Roser in 2003 and is headquartered in UK. | Health Technology |
IGEN International, Inc.
IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | Health Technology |
ACE BioSciences ApS
ACE BioSciences ApS Pharmaceuticals: MajorHealth Technology ACE BioSciences A/S engages in the research and experimental development on biotechnology. It offers medical research, production, and sale of medical products. The company was founded on September 15, 2000 and is headquartered in Hillerød, Denmark. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
TD Vaccines A/S
TD Vaccines A/S Pharmaceuticals: MajorHealth Technology TD Vaccines A/S S is a holding company that focuses on the development of vaccines to protect against travellers' diarrhoea (TD). It is a biotechnology company that discovers and develops novel vaccines to fight serious bacterial infections. Its lead programme is ACE527, an oral ETEC vaccine to protect against ETEC (Enterotoxigenic E Coli). Its oral combination vaccine, ACE920, designs to protect against ETEC and Campylobacter infections. The company was founded in November 2009 and is headquartered in Skorping, Denmark. | Health Technology |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |